IMUNON
Clinical trials sponsored by IMUNON, explained in plain language.
IMUNON
IMNN
NASDAQ
Clinical-stage biopharmaceutical company developing DNA-based immunotherapies and vaccines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo aims to wipe out hidden ovarian cancer cells Results expected Jun 2027 (estimated)